Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-06-24
2011-10-11
Landau, Sharmila G. (Department: 1611)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S044000
Reexamination Certificate
active
08034825
ABSTRACT:
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
REFERENCES:
patent: 4223163 (1980-09-01), Guilloty
patent: 4366159 (1982-12-01), Magruder
patent: 4489079 (1984-12-01), Giudice et al.
patent: 4587046 (1986-05-01), Goodman et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4719215 (1988-01-01), Goldberg
patent: 4730048 (1988-03-01), Portoghese
patent: 4801575 (1989-01-01), Pardridge
patent: 4806556 (1989-02-01), Portoghese
patent: 4861781 (1989-08-01), Goldberg
patent: 5053228 (1991-10-01), Mori et al.
patent: 5099074 (1992-03-01), Mueller et al.
patent: 5102887 (1992-04-01), Goldberg
patent: 5122614 (1992-06-01), Zalipsky
patent: 5130126 (1992-07-01), Koyama et al.
patent: 5159081 (1992-10-01), Cantrell et al.
patent: 5225206 (1993-07-01), Fushimi et al.
patent: 5250542 (1993-10-01), Cantrell et al.
patent: 5270328 (1993-12-01), Cantrell et al.
patent: 5298410 (1994-03-01), Phillips et al.
patent: 5320840 (1994-06-01), Camble et al.
patent: 5428128 (1995-06-01), Mensi-Fattohi et al.
patent: 5434171 (1995-07-01), Frank et al.
patent: 5442043 (1995-08-01), Fukuta et al.
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5567422 (1996-10-01), Greenwald
patent: 5569450 (1996-10-01), Duan et al.
patent: 5612460 (1997-03-01), Zalipsky
patent: 5618926 (1997-04-01), Salamone et al.
patent: 5637749 (1997-06-01), Greenwald
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5714639 (1998-02-01), Bowman et al.
patent: 5854208 (1998-12-01), Jones et al.
patent: 5866164 (1999-02-01), Kuczynski et al.
patent: 5922675 (1999-07-01), Baker et al.
patent: 5972954 (1999-10-01), Foss et al.
patent: 6011008 (2000-01-01), Domb et al.
patent: 6316644 (2001-11-01), Chung et al.
patent: 6362254 (2002-03-01), Harris et al.
patent: 6380405 (2002-04-01), Ekwuribe et al.
patent: 6419959 (2002-07-01), Walter et al.
patent: 6451806 (2002-09-01), Farrar
patent: 6461603 (2002-10-01), Bentley et al.
patent: 6515100 (2003-02-01), Harris
patent: 6518239 (2003-02-01), Kuo et al.
patent: 6541508 (2003-04-01), Ekwuribe et al.
patent: 6565885 (2003-05-01), Tarara et al.
patent: 6703381 (2004-03-01), Ekwuribe et al.
patent: 6713454 (2004-03-01), Ekwuribe et al.
patent: 6713488 (2004-03-01), Sade et al.
patent: 6815530 (2004-11-01), Ekwuribe et al.
patent: 6835802 (2004-12-01), Ekwuribe et al.
patent: 6858580 (2005-02-01), Ekwuribe et al.
patent: 6903082 (2005-06-01), Ekwuribe et al.
patent: 6930090 (2005-08-01), Ekwuribe et al.
patent: 6943148 (2005-09-01), Ekwuribe et al.
patent: 7056500 (2006-06-01), Bentley et al.
patent: 7662365 (2010-02-01), Bentley et al.
patent: 2002/0169125 (2002-11-01), Leung et al.
patent: 2002/0182172 (2002-12-01), Bentley et al.
patent: 2003/0044402 (2003-03-01), Nelson
patent: 2003/0105275 (2003-06-01), Bentley et al.
patent: 2003/0124086 (2003-07-01), Bentley et al.
patent: 2003/0161791 (2003-08-01), Bentley et al.
patent: 2003/0203961 (2003-10-01), Ekwuribe et al.
patent: 2004/0023852 (2004-02-01), Roberts et al.
patent: 2004/0082620 (2004-04-01), Craig et al.
patent: 2006/0105046 (2006-05-01), Bentley et al.
patent: 2009/0221766 (2009-09-01), Cheng et al.
patent: 2010/0105715 (2010-04-01), Bentley et al.
patent: 19632440 (1998-02-01), None
patent: 0822218 (1998-02-01), None
patent: 0995757 (2000-04-01), None
patent: 01207320 (1989-08-01), None
patent: WO 93/24476 (1993-12-01), None
patent: WO 96/21469 (1996-07-01), None
patent: WO 97/14740 (1997-04-01), None
patent: WO 99/30727 (1999-06-01), None
patent: WO 99/45964 (1999-09-01), None
patent: WO 01/12230 (2001-02-01), None
patent: WO 01/19407 (2001-03-01), None
patent: WO 01/47562 (2001-07-01), None
patent: WO 01/62299 (2001-08-01), None
patent: WO 02/43772 (2002-06-01), None
patent: WO 02/065988 (2002-08-01), None
patent: WO 02/089789 (2002-11-01), None
patent: WO 02/098949 (2002-12-01), None
patent: WO 03/032990 (2003-04-01), None
patent: WO 03/037384 (2003-05-01), None
patent: WO 03/037385 (2003-05-01), None
patent: WO 03/051113 (2003-06-01), None
patent: WO 03/079972 (2003-10-01), None
patent: WO 03/101476 (2003-12-01), None
patent: WO 2004/043396 (2004-05-01), None
patent: WO 2004/082620 (2004-09-01), None
patent: WO 2005/012335 (2005-02-01), None
patent: WO 2005/016240 (2005-02-01), None
patent: WO 2005/051327 (2005-06-01), None
patent: WO/2005/058367 (2005-06-01), None
Asai et al., “Naloxone Inhibits Gastric Emptying in the Rat”, Anesth. Analg., 1999, pp. 204-208, vol. 88.
Batz et al., “Pharmakologisch aktive Polymere,” Arzneimittel-Forshung 1977 pp. 1884-1888 (English summary provided).
Bennett et al., “Drug-Coupled Poly(Amino Acids) as Polymeric Prodrugs”, Journal of Bioactive and Compatible Polymers, 1988, pp. 44-52, vol. 3.
Bennett et al., “Biodegradable Polymeric Prodrugs of Naltrexone”, Journal of Controlled Release, 1991, pp. 43-52, vol. 16, Nos. 1/2.
Davies, et al., “Physiological Parameters in Laboratory Animals and Humans,” Pharrn. Res. vol. 10, Issue 7, p. 1093-1095, 1993.
Donovan, et al., “Absorption of Polyethylene Glycols 600 Through 2000: The Molecular Weight Dependence of Gastrointestinal and Nasal Absorption,” Pharrn. Res., vol. 7, Issue 8, 1990.
Eldon, et al., “NKTR-118 (Oral PEG-Naloxol), a PEGylated Derivative of Naloxone: Demonstrations of Selective Peripheral Opioid Antagonism After Oral Administration in Preclinical Models,” Poster 28 presented at the American Academy of Pain Management 18thAnnual Clinical Meeting; Sep. 27-30, 2007; Las Vegas, NV.
Enzon Pharmaceuticals, Macromolecular Engineering Technologies, pp. 1-14, (2004).
Erez et al, “Narcotic Antagonistic Potency of Bivalent Ligands Which Contain B-Naltrexarnine. Evidence for Bridging between Proximal Recognition Sites”,J. Med. Chem., 1982, pp. 847-849, vol. 25, No. 7.
Ertl et al., “Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”, J. Med. Chem., 2000; pp. 3714-3717, vol. 43.
Fishburn, et al., “The Pharmacology of PEGylation: Balancing PO with PK to Generate Novel Therapeutics,” J. Pharm. Sci., p. 1-17,2008.
Fishman, J., et al., “Preparation and Evaluation of a Sustained Naloxone Delivery System in Rats”, Pharmacology, 1975, pp. 513-519, vol. 13(6).
Flanagan et al., “Affinity Partitioning: A Method for Purification of Proteins Using Specific Polymer-Ligands in Aqueous Polymer Two-Phase Systems”, The Journal of Biological Chemistry, 1975; pp. 1484-1489, vol. 250, No. 4.
Greenwald et al., “Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Polyz(ethylene glycol) Prodrugs of Amine-Containing Compounds,” J. Med. Chern., No. 42, p. 3657-3667 (1999).
Greenwald et al., “Drug Delivery Systems Based on Trimethyl Lock Lactonization: Poly(ethylene glycol) Prodrgus of Amino-Containing Compounds,” J. Med Chern., No. 43, p. 475-487, (2000).
Greenwald, et al., “Effective drug delivery by PEGylated drug conjugates,” Adv. Drug Deliv. Rev., vol. 55, p. 217-250, 2003.
Greenwald, R., et al., “Highly Water Soluble Taxol Derivatives: 7-Polyethylene Glycol Carbamates and Carbonates”, J. Org. Chem., 1995, pp. 331-336, vol. 60.
Harris, et al., “Effect of PEGylation on Pharmaceuticals,” Nat. Rev. Drug Discov., vol. 11, Issue. 3, p. 214-221, Mar. 2003.
Harris, et al., “Pegylation: A Novel Process for Modifying Pharmacokinetics,” Clin. Pharmacokinet., vol. 40, No. 7, p. 539-551, 2001.
Harris, J. M., ed., “Poly(Ethylene Glycol) Chemistry&#x
Bentley Michael D.
Cheng Lin
Goodin Richard R.
Viegas Tacey X.
Zhao Xuan
Jones Day
Landau Sharmila G.
Love Trevor
Nektar Therapeutics
LandOfFree
Chemically modified small molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemically modified small molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemically modified small molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4266337